

James R Connor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7411349/publications.pdf>

Version: 2024-02-01

78
papers

4,653
citations

147801

31
h-index

106344

65
g-index

82
all docs

82
docs citations

82
times ranked

5131
citing authors

#	ARTICLE	IF	CITATIONS
1	Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas. <i>Neuro-Oncology</i> , 2022, 24, 302-310.	1.2	29
2	Biological Activity of a Thiobarbituric Acid Compound in Neuroblastomas. <i>Anticancer Research</i> , 2021, 41, 1171-1181.	1.1	4
3	Association Between Iron and Cholesterol in Neuroblastomas. <i>Anticancer Research</i> , 2021, 41, 2795-2804.	1.1	1
4	OMIC-10. TRANSCRIPTOMIC ANALYSIS REVEALS SEX DIFFERENCES IN PEDIATRIC BRAIN MECHANISMS. <i>Neuro-Oncology</i> , 2021, 23, i39-i39.	1.2	0
5	Low plasma serotonin linked to higher nigral iron in Parkinson's disease. <i>Scientific Reports</i> , 2021, 11, 24384.	3.3	7
6	Transferrin and H-ferritin involvement in brain iron acquisition during postnatal development: impact of sex and genotype. <i>Journal of Neurochemistry</i> , 2020, 152, 381-396.	3.9	24
7	The roles of iron and HFE genotype in neurological diseases. <i>Molecular Aspects of Medicine</i> , 2020, 75, 100867.	6.4	27
8	Characterization of a Novel Barbituric Acid and Two Thiobarbituric Acid Compounds for Lung Cancer Treatment. <i>Anticancer Research</i> , 2020, 40, 6039-6049.	1.1	11
9	High-affinity mutant Interleukin-13 targeted CAR T cells enhance delivery of clickable biodegradable fluorescent nanoparticles to glioblastoma. <i>Bioactive Materials</i> , 2020, 5, 624-635.	15.6	34
10	H63D variant of the homeostatic iron regulator (HFE) gene alters α -synuclein expression, aggregation, and toxicity. <i>Journal of Neurochemistry</i> , 2020, 155, 177-190.	3.9	9
11	Gliomas display distinct sex-based differential methylation patterns based on molecular subtype. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa002.	0.7	15
12	JAM-A functions as a female microglial tumor suppressor in glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 1591-1601.	1.2	26
13	Sexually dimorphic impact of the iron-regulating gene, HFE, on survival in glioblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa001.	0.7	2
14	Evidence for communication of peripheral iron status to cerebrospinal fluid: clinical implications for therapeutic strategy. <i>Fluids and Barriers of the CNS</i> , 2020, 17, 28.	5.0	6
15	Endothelial cells are critical regulators of iron transport in a model of the human blood-brain barrier. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 2117-2131.	4.3	75
16	Exosomes and their implications in central nervous system tumor biology. <i>Progress in Neurobiology</i> , 2019, 172, 71-83.	5.7	26
17	Liposomal delivery of ferritin heavy chain 1 (FTH1) siRNA in patient xenograft derived glioblastoma initiating cells suggests different sensitivities to radiation and distinct survival mechanisms. <i>PLoS ONE</i> , 2019, 14, e0221952.	2.5	13
18	Iron uptake at the blood-brain barrier is influenced by sex and genotype. <i>Advances in Pharmacology</i> , 2019, 84, 123-145.	2.0	16

#	ARTICLE	IF	CITATIONS
19	Iron, Myelin, and the Brain: Neuroimaging Meets Neurobiology. <i>Trends in Neurosciences</i> , 2019, 42, 384-401.	8.6	123
20	Semaphorin4A causes loss of mature oligodendrocytes and demyelination in vivo. <i>Journal of Neuroinflammation</i> , 2019, 16, 28.	7.2	9
21	Oroxylum indicum (L.) extract protects human neuroblastoma SH-SY5Y cells against β -amyloid-induced cell injury. <i>Molecular Medicine Reports</i> , 2019, 20, 1933-1942.	2.4	13
22	HFE Genotype Restricts the Response to Paraquat in a Mouse Model of Neurotoxicity. <i>Journal of Neurochemistry</i> , 2018, 145, 299-311.	3.9	19
23	Emerging and Dynamic Biomedical Uses of Ferritin. <i>Pharmaceuticals</i> , 2018, 11, 124.	3.8	67
24	Pharmaceutical iron formulations do not cross a model of the human blood-brain barrier. <i>PLoS ONE</i> , 2018, 13, e0198775.	2.5	15
25	A Possible Role for Platelet-Activating Factor Receptor in Amyotrophic Lateral Sclerosis Treatment. <i>Frontiers in Neurology</i> , 2018, 9, 39.	2.4	9
26	Tumor targeted delivery of doxorubicin in malignant peripheral nerve sheath tumors. <i>PLoS ONE</i> , 2018, 13, e0181529.	2.5	6
27	Exosomes impact survival to radiation exposure in cell line models of nervous system cancer. <i>Oncotarget</i> , 2018, 9, 36083-36101.	1.8	54
28	The Relationship Between Iron Deficiency Anemia and Sensorineural Hearing Loss in the Pediatric and Adolescent Population. <i>American Journal of Audiology</i> , 2017, 26, 155-162.	1.2	24
29	HFE genotype affects exosome phenotype in cancer. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 1921-1928.	2.4	12
30	Interleukin-13 conjugated quantum dots for identification of glioma initiating cells and their extracellular vesicles. <i>Acta Biomaterialia</i> , 2017, 58, 205-213.	8.3	45
31	Regulatory mechanisms for iron transport across the blood-brain barrier. <i>Biochemical and Biophysical Research Communications</i> , 2017, 494, 70-75.	2.1	40
32	Statins accelerate disease progression and shorten survival in SOD1 ^{G93A} mice. <i>Muscle and Nerve</i> , 2016, 54, 284-291.	2.2	23
33	Increased R2* in the Caudate Nucleus of Asymptomatic Welders. <i>Toxicological Sciences</i> , 2016, 150, 369-377.	3.1	18
34	MRI contrast agent for targeting glioma: interleukin-13 labeled liposome encapsulating gadolinium-DTPA. <i>Neuro-Oncology</i> , 2016, 18, 691-699.	1.2	48
35	Semaphorin4A Is Cytotoxic to Oligodendrocytes and Is Elevated in Microglia and Multiple Sclerosis. <i>ASN Neuro</i> , 2015, 7, 175909141558750.	2.7	18
36	The effects of okra (<i>Abelmoschus esculentus</i> Linn.) on the cellular events associated with Alzheimer's disease in a stably expressed HFE neuroblastoma SH-SY5Y cell line. <i>Neuroscience Letters</i> , 2015, 603, 6-11.	2.1	15

#	ARTICLE	IF	CITATIONS
37	HFE polymorphisms affect survival of brain tumor patients. <i>Journal of Neuro-Oncology</i> , 2015, 122, 97-104.	2.9	6
38	Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells. <i>Cancer Cell</i> , 2015, 28, 441-455.	16.8	249
39	The HFE genotype and a formulated diet controlling for iron status attenuate experimental cerebral malaria in mice. <i>International Journal for Parasitology</i> , 2015, 45, 797-808.	3.1	6
40	The relationship between iron dyshomeostasis and amyloidogenesis in Alzheimer's disease: Two sides of the same coin. <i>Neurobiology of Disease</i> , 2015, 81, 49-65.	4.4	115
41	From adaption to death: endoplasmic reticulum stress as a novel target of selective neurodegeneration?. <i>Neural Regeneration Research</i> , 2015, 10, 1397.	3.0	6
42	Characterization of a Novel Anti-Cancer Compound for Astrocytomas. <i>PLoS ONE</i> , 2014, 9, e108166.	2.5	10
43	HFE gene variants, iron, and lipids: a novel connection in Alzheimer's disease. <i>Frontiers in Pharmacology</i> , 2014, 5, 165.	3.5	33
44	H63D mutation in hemochromatosis alters cholesterol metabolism and induces memory impairment. <i>Neurobiology of Aging</i> , 2014, 35, 1511.e1-1511.e12.	3.1	25
45	H63D HFE genotype accelerates disease progression in animal models of amyotrophic lateral sclerosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 2413-2426.	3.8	26
46	A mutation in the HFE gene is associated with altered brain iron profiles and increased oxidative stress in mice. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 729-741.	3.8	51
47	H63D HFE polymorphisms are associated with increased disease duration and decreased muscle superoxide dismutase-1 expression in amyotrophic lateral sclerosis patients. <i>Muscle and Nerve</i> , 2013, 48, 242-246.	2.2	13
48	Postmortem and imaging based analyses reveal CNS decreased myelination in restless legs syndrome. <i>Sleep Medicine</i> , 2011, 12, 614-619.	1.6	72
49	Mutant HFE H63D Protein Is Associated with Prolonged Endoplasmic Reticulum Stress and Increased Neuronal Vulnerability. <i>Journal of Biological Chemistry</i> , 2011, 286, 13161-13170.	3.4	43
50	Profile of altered brain iron acquisition in restless legs syndrome. <i>Brain</i> , 2011, 134, 959-968.	7.6	203
51	Bone Structural and Mechanical Properties Are Affected by Hypotransferrinemia But Not by Iron Deficiency in Mice. <i>Journal of Bone and Mineral Research</i> , 2010, 15, 271-277.	2.8	8
52	Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. <i>Brain</i> , 2009, 132, 2403-2412.	7.6	299
53	Pathophysiology of restless legs syndrome: Evidence for iron involvement. <i>Current Neurology and Neuroscience Reports</i> , 2008, 8, 162-166.	4.2	55
54	Comparative study of the influence of Thy1 deficiency and dietary iron deficiency on dopaminergic profiles in the mouse striatum. <i>Journal of Neuroscience Research</i> , 2008, 86, 3194-3202.	2.9	12

#	ARTICLE	IF	CITATIONS
55	Consequences of expressing mutants of the hemochromatosis gene (HFE) into a human neuronal cell line lacking endogenous HFE. FASEB Journal, 2007, 21, 564-576.	0.5	56
56	Proteomic analysis of CSF can identify iron deficient monkeys. FASEB Journal, 2007, 21, A1117.	0.5	0
57	O-glycosylation regulates H-ferritin transport into the nucleus. FASEB Journal, 2007, 21, A990.	0.5	0
58	Characterization of Hfe mutations in brain tumor cells. FASEB Journal, 2006, 20, A509.	0.5	0
59	Myelin breakdown in Alzheimer's disease: a commentary. Neurobiology of Aging, 2004, 25, 45-47.	3.1	14
60	The case for iron chelation and/or antioxidant therapy in Alzheimer's disease. Drug Development Research, 2002, 56, 526-530.	2.9	15
61	Characterization of a novel brain-derived microglial cell line isolated from neonatal rat brain. Glia, 2001, 35, 53-62.	4.9	153
62	Insight into the pathophysiology of restless legs syndrome. Journal of Neuroscience Research, 2000, 62, 623-628.	2.9	209
63	Identification of iron responsive genes by screening cDNA libraries from suppression subtractive hybridization with antisense probes from three iron conditions. Nucleic Acids Research, 2000, 28, 1802-1807.	14.5	51
64	Insight into the pathophysiology of restless legs syndrome. Journal of Neuroscience Research, 2000, 62, 623-628.	2.9	1
65	Existing and emerging mechanisms for transport of iron and manganese to the brain. , 1999, 56, 113-122.		123
66	Evidence for non-transferrin-mediated uptake and release of iron and manganese in glial cell cultures from hypotransferrinemic mice. , 1998, 51, 454-462.		58
67	Cellular distribution of ferritin subunits in postnatal rat brain. Journal of Comparative Neurology, 1998, 400, 73-86.	1.6	113
68	Relationship of iron to oligodendrocytes and myelination. Glia, 1996, 17, 83-93.	4.9	607
69	Demonstration and Characterization of the Iron Regulatory Protein in Human Brain. Journal of Neurochemistry, 1996, 67, 838-844.	3.9	34
70	Relationship of iron to oligodendrocytes and myelination. , 1996, 17, 83.		3
71	Cellular distribution of iron, transferrin, and ferritin in the hypotransferrinemic (Hp) mouse brain. Journal of Comparative Neurology, 1995, 355, 67-80.	1.6	61
72	Iron Regulation in the Developing Rat Brain: Effect of In Utero Ethanol Exposure. Journal of Neurochemistry, 1995, 65, 373-380.	3.9	54

#	ARTICLE	IF	CITATIONS
73	A Quantitative Analysis of Isoferritins in Select Regions of Aged, Parkinsonian, and Alzheimer's Diseased Brains. <i>Journal of Neurochemistry</i> , 1995, 65, 717-724.	3.9	290
74	Iron, Transferrin, and Ferritin in the Rat Brain During Development and Aging. <i>Journal of Neurochemistry</i> , 1994, 63, 709-716.	3.9	151
75	Ferritin, transferrin, and iron in selected regions of the adult and aged rat brain. <i>Journal of Comparative Neurology</i> , 1993, 338, 97-113.	1.6	222
76	Iron regulation in the brain: Histochemical, biochemical, and molecular considerations. <i>Annals of Neurology</i> , 1992, 32, S51-S61.	5.3	155
77	Expression of Transferrin mRNA in the CNS of Normal and Jimpy Mice. <i>Journal of Neurochemistry</i> , 1991, 57, 318-322.	3.9	81
78	Do oligodendrocytes mediate iron regulation in the human brain?. <i>Annals of Neurology</i> , 1989, 26, 95-98.	5.3	84